AACR 2026: GenFleet Therapeutics Announces Preclinical Data of GFH276, a Molecular Glue Pan RAS (ON) Inhibitor, Demonstrates Lower Preclinical Effective Dose and Synergistic Efficacy with Multiple Standard-of-care Therapies

File

2026042202 e.pdf